SPX3,719.04+71.75 1.97%
DIA296.73+5.43 1.86%
IXIC11,051.64+222.13 2.05%

eFFECTOR Therapeutics Doses First Patient In Second Cohort Of Phase 1b Clinical Trial Of Zotatifin For Treatment Of COVID-19

- Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 -   - Drug levels achieved with sub-cutaneous formulation equivalent to IV

Benzinga · 09/14/2022 08:09

- Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 -
 

- Drug levels achieved with sub-cutaneous formulation equivalent to IV formulation -